Hubei Biocause Pharmaceutical Co., Ltd. (SHE: 000627)
China
· Delayed Price · Currency is CNY 2.900
+0.260 (9.85%)
Sep 9, 2024, 1:41 PM CST
Hubei Biocause Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Premiums & Annuity Revenue | 36,552 | 40,321 | 37,768 | 37,384 | 28,896 | 37,576 | Upgrade
|
| Total Interest & Dividend Income | 7,209 | 7,426 | 10,364 | 9,834 | 10,219 | 9,797 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1,538 | -1,496 | -888.46 | -686.96 | 1,580 | 91.06 | Upgrade
|
| Non-Insurance Activities Revenue | 1,624 | 1,922 | 1,713 | 1,758 | 1,667 | 2,060 | Upgrade
|
| Other Revenue | 68.29 | 104.88 | 355.85 | 408.31 | -1,233 | 148.89 | Upgrade
|
| Total Revenue | 43,915 | 48,278 | 49,312 | 48,697 | 41,128 | 49,673 | Upgrade
|
| Revenue Growth (YoY) | -20.40% | -2.10% | 1.26% | 18.40% | -17.20% | 66.25% | Upgrade
|
| Policy Benefits | 38,358 | 40,161 | 40,950 | 40,290 | 36,140 | 37,097 | Upgrade
|
| Policy Acquisition & Underwriting Costs | 1,596 | 3,131 | 3,061 | 3,410 | 2,382 | 3,543 | Upgrade
|
| Selling, General & Administrative | 1,775 | 1,759 | 1,646 | 1,429 | -1,672 | 2,108 | Upgrade
|
| Provision for Bad Debts | - | - | - | -8.23 | -0.65 | 10.14 | Upgrade
|
| Non-Insurance Activities Expense | - | - | - | - | 2,870 | 3,282 | Upgrade
|
| Other Operating Expenses | 2,970 | 3,811 | 3,549 | 3,001 | 45.68 | 59.77 | Upgrade
|
| Total Operating Expenses | 45,994 | 50,158 | 49,206 | 48,397 | 40,029 | 46,229 | Upgrade
|
| Operating Income | -2,079 | -1,880 | 105.86 | 300.64 | 1,100 | 3,444 | Upgrade
|
| Currency Exchange Gain (Loss) | -10.87 | 20.47 | 72.02 | -15.2 | -33.9 | -1.52 | Upgrade
|
| Other Non Operating Income (Expenses) | 3.55 | - | - | - | - | -20.67 | Upgrade
|
| EBT Excluding Unusual Items | -2,021 | -1,859 | 177.87 | 285.44 | 1,066 | 3,422 | Upgrade
|
| Gain (Loss) on Sale of Assets | 2.81 | 0.95 | 0.42 | -0.43 | -0.31 | 1.59 | Upgrade
|
| Asset Writedown | -1.31 | -0.77 | -0.16 | -0.25 | -0.16 | -0.34 | Upgrade
|
| Other Unusual Items | -0.48 | -9.01 | 46.65 | 58.35 | 384.22 | 210.53 | Upgrade
|
| Pretax Income | -2,020 | -1,868 | 224.78 | 343.12 | 1,449 | 3,633 | Upgrade
|
| Income Tax Expense | -401.11 | -586.5 | -285.84 | -537.09 | 331.56 | 714.89 | Upgrade
|
| Earnings From Continuing Ops. | -1,618 | -1,281 | 510.62 | 880.22 | 1,118 | 2,919 | Upgrade
|
| Minority Interest in Earnings | 789.11 | 629.74 | -236.57 | -409.5 | -537.61 | -1,143 | Upgrade
|
| Net Income | -829.39 | -651.76 | 274.05 | 470.71 | 580.29 | 1,776 | Upgrade
|
| Net Income to Common | -829.39 | -651.76 | 274.05 | 470.71 | 580.29 | 1,776 | Upgrade
|
| Net Income Growth | - | - | -41.78% | -18.88% | -67.32% | 33.88% | Upgrade
|
| Shares Outstanding (Basic) | 5,014 | 5,014 | 4,568 | 4,707 | 4,836 | 4,933 | Upgrade
|
| Shares Outstanding (Diluted) | 5,014 | 5,014 | 4,568 | 4,707 | 4,836 | 4,933 | Upgrade
|
| Shares Change (YoY) | 9.32% | 9.76% | -2.97% | -2.66% | -1.97% | 0.41% | Upgrade
|
| EPS (Basic) | -0.17 | -0.13 | 0.06 | 0.10 | 0.12 | 0.36 | Upgrade
|
| EPS (Diluted) | -0.17 | -0.13 | 0.06 | 0.10 | 0.12 | 0.36 | Upgrade
|
| EPS Growth | - | - | -40.00% | -16.67% | -66.67% | 33.33% | Upgrade
|
| Free Cash Flow | -23,720 | 9,467 | 7,389 | 3,885 | 21,102 | 27,882 | Upgrade
|
| Free Cash Flow Per Share | -4.73 | 1.89 | 1.62 | 0.83 | 4.36 | 5.65 | Upgrade
|
| Dividend Per Share | - | - | 0.110 | 0.005 | 0.010 | 0.130 | Upgrade
|
| Dividend Growth | - | - | 2100.00% | -50.00% | -92.31% | 333.33% | Upgrade
|
| Operating Margin | -4.73% | -3.89% | 0.21% | 0.62% | 2.67% | 6.93% | Upgrade
|
| Profit Margin | -1.89% | -1.35% | 0.56% | 0.97% | 1.41% | 3.58% | Upgrade
|
| Free Cash Flow Margin | -54.01% | 19.61% | 14.98% | 7.98% | 51.31% | 56.13% | Upgrade
|
| EBITDA | -1,975 | -1,778 | 196.8 | 388.79 | 1,163 | 3,523 | Upgrade
|
| EBITDA Margin | -4.50% | -3.68% | 0.40% | 0.80% | 2.83% | 7.09% | Upgrade
|
| D&A For EBITDA | 103.61 | 101.24 | 90.94 | 88.15 | 63.66 | 79.17 | Upgrade
|
| EBIT | -2,079 | -1,880 | 105.86 | 300.64 | 1,100 | 3,444 | Upgrade
|
| EBIT Margin | -4.73% | -3.89% | 0.21% | 0.62% | 2.67% | 6.93% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 22.87% | 19.68% | Upgrade
|
| Revenue as Reported | 45,324 | 49,699 | 49,616 | 49,583 | 41,200 | 50,192 | Upgrade
|
Source: S&P Capital IQ. Insurance template. Financial Sources.